Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma

Commentary
Video

The medical oncologist and clinical director of Myeloma Cellular Therapies at Dana-Farber Cancer Institute emphasized promising safety in patients with high-risk disease.

“This [presentation is] basically highlighting the activity of this GPRC5D CAR T-cell product in earlier rounds of therapy in a high-risk patient population, the favorable toxicity profile, and a very high response rate of 96% with a complete response rate of 32%.”

BMS-986393, a GPRC5D-targeted chimeric antigen receptor (CAR) T-cell therapy, was well-tolerated and yielded responses in patients with multiple myeloma and 1-to-3 lines of prior therapy.

Initial data from the phase 1 CC95266MM001 study (NCT04674813) evaluating BMS-986393 were presented at the European Hematology Association 2024 Hybrid Congress, held June 13-16 in Madrid, Spain, and virtually, by Omar Nadeem, MD, medical oncologist and clinical director, Myeloma Cellular Therapies Program, Dana-Farber Cancer Institute and instructor in medicine, Harvard Medical School.

The data are from 31 participants in the study who received 150 x 106 CAR T cells. Only 1 patient had received prior anti-BCMA therapy. Investigators found that overall response rate of 96%, with a complete responses rate of 32%, although median follow-up time was only 3.2 months (range, 0.5–5.8) at the time of data cutoff. CGTLive® spoke with Nadeem to learn more about the new data. He shared that the therapy's toxicity profile was as expected and gave an overview of treatment-emergent adverse events that occurred, including some neurological toxicities. He noted that follow-up time was short in this data and that responses may deepen as follow-up lengthens.

REFERENCE
Nadeem O, Htut M, Berdeja J, et al. Safety and Preliminary Efficacy of BMS-986393, a GPRC5D CAR T-cell Therapy, in Patients With Relapsed/Refractory (RR) Multiple Myeloma (Mm) and 1–3 Prior Regimens: First Results From a Phase 1 Study. Presented at: EHA2024 Hybrid Congress, June 13-16; Madrid, Spain. Poster #P951
Recent Videos
Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Related Content
© 2024 MJH Life Sciences

All rights reserved.